Early Progressive Disease Predicts Poor Outcomes of Second-line VEGFR Tyrosine Kinase Inhibitor Therapy After First-line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma.

BACKGROUND/AIM: The optimal treatment sequence after first-line nivolumab plus ipilimumab (Nivo+Ipi) for advanced renal cell carcinoma remains unclear, particularly for patients with early progressive disease (PD). We evaluated the effectiveness of second-line vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) therapy after Nivo+Ipi according to early PD status. PATIENTS AND METHODS: This retrospective single-center study included patients with advanced renal cell carcinoma treated at Kyushu Cancer Center between September 2018 and January 2026. Among 54 patients who received systemic therapy, 40 were treated with first-line Nivo+Ipi. We analyzed 21 patients who subsequently received second-line VEGFR-TKI therapy (cabozantinib or axitinib). Early PD was defined as PD within 12 weeks of Nivo+Ipi initiation. Best response and progression-free survival (PFS) after second-line therapy were compared between early PD and non-early PD groups. A sensitivity analysis was performed among patients treated with cabozantinib. CONCLUSION: Early PD after first-line Nivo+Ipi was associated with no objective response and markedly shorter PFS with second-line VEGFR-TKI. These findings suggest that early PD may identify a high-risk subgroup with limited benefit from standard second-line VEGFR-TKI treatment.